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Abstract
Introduction: Anti-Ro antibodies can be found in the serum of the majority of patients with Sjo ¨gren’s syndrome (SS).
Immunization with a 60-kDa Ro peptide has been shown to induce SS-like symptoms in mice. The aim of this study was to
investigate factors involved in salivary gland (SG) dysfunction after immunization and to test whether the induction of SS
could be improved.
Methods: Ro60 peptide immunization was tested in Balb/c mice, multiple antigenic peptide (MAP)-Ro60 and Pertussis toxin
(PTX) were tested in SJL/J mice. In addition, two injection sites were compared in these two strains: the abdominal area and
the tailbase. Each group of mice was tested for a loss of SG function, SG lymphocytic infiltration, anti-Ro and anti-La
antibody formation, and cytokine production in cultured cells or homogenized SG extracts.
Results: Ro60 peptide immunization in the abdominal area of female Balb/c mice led to impaired SG function, which
corresponded with increased Th1 cytokines (IFN-c and IL-12) systemically and locally in the SG. Moreover, changing the
immunization conditions to MAP-Ro60 in the abdominal area, and to lesser extend in the tailbase, also led to impaired SG
function in SJL/J mice. As was seen in the Balb/c mice, increased IFN-c in the SG draining lymph nodes accompanied the SG
dysfunction. However, no correlation was observed with anti-MAP-Ro60 antibody titers, and there was no additional effect
on disease onset or severity.
Conclusions: Effective induction of salivary gland dysfunction after Ro60 peptide immunization depended on the site of
injection. Disease induction was not affected by changing the immunization conditions. However, of interest is that the
mechanism of action of Ro60 peptide immunization appears to involve an increase in Th1 cytokines, resulting in the
induction of SG dysfunction.
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Introduction
Sjo ¨gren’s syndrome (SS) is a systemic autoimmune disorder of
unknown etiology. This autoimmune exocrinopathy is character-
ized by mononuclear cell infiltration in exocrine glands,
principally the lachrymal and salivary glands (SGs). In serum,
.75% of SS patients have autoantibodies against the nuclear
antigens Ro (SSA) and La (SSB). These antibodies are associated
with SS, but are not unique to the disease [1]. The pathogenic
relevance of these autoantibodies is not clear and other
autoantibodies involved in neuronal innervation, aquaporins,
matrix metalloproteinases, and apoptosis have also been identified
to be involved in the pathogenesis of SS (as reviewed in [2]).
To better understand the pathogenesis of the most common
autoantibodies in SS, various animal models have been established
by focusing on anti-Ro and La antibodies [3,4]. Balb/c mice
immunized with short Ro60 peptides developed anti-Ro and -La
antibodies, SG lymphocytic infiltrates, and SG dysfunction, also
seen in SS patients [5]. In addition, although the pathogenic
function of autoantibodies against Ro and La is not clear, a
number of previous studies imply that enhanced pro-inflammatory
cytokines, such as interferon (IFN)-c, interleukin (IL)-18 and IL-
17, are highly related to increased anti-Ro antibody levels in SS
[6]. This suggests a possible correlation between anti-Ro
antibodies and autoimmune T cell mediated responses in SS.
Moreover, previous studies from our own group have shown the
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gland dysfunction [4,7,8]. Therefore, we have set up the same
model to investigate the induction of SS-like symptoms, and the
role of cytokines in SG dysfunction after Ro60 peptide
immunization.
It was previously shown that only 30% of the immunized mice
develop SG foci and variability in SG dysfunction was observed
[5]. To further optimize this animal model, we tested other
conditions for SS disease induction using the same peptide, and
switched to SJL/J mice, a well established autoimmune prone
animal model [9,10]. We also added Pertussis toxin (PTX) to our
peptide emulsion, which is an important additional adjuvant in
experimental autoimmune uveoretinitis (EAU) in B10.A mice [11].
Moreover, based on our own experience (unpublished data,
Roescher et al.) and on the literature [12,13], higher antibody
titers can be achieved by immunizing with a multiple antigenic
peptide (MAP) instead of the conventional peptide. Therefore, we
have immunized mice with MAP-Ro60 peptide and tested in two
different injection sites for its effect on disease onset.
Results
Induction of anti-Ro60 antibodies and salivary gland
dysfunction in Balb/c
Balb/c mice were immunized with Ro60 peptide as previously
described [5], and the induction of anti-Ro60 antibodies was
assessed at day 17, 37 and 70. Both tailbase and abdominal area
immunized Balb/c mice showed a significant increase in anti-
MAP-Ro60 antibodies (p,0.0001) following the first boost, and
this was sustained throughout the whole study (Figure 1A).
To investigate the effect of Ro60 peptide immunization on SG
function, stimulated salivary flow was measured. Immunization
with Ro60 peptide at the tailbase showed on day 70 a modest
decrease in salivary flow rate (SFR) compared with controls
(p=0.04, Figure 1B). Changing the injection site to the abdominal
area resulted in a more pronounced decrease in saliva production
on day 70 (p,0.0001, Figure 1B). In addition, on day 17, a
transient decrease in SFR following immunization in the
abdominal area was observed (p=0.02). These data confirm
Figure 1. Increased anti-Ro60 antibodies and salivary gland dysfunction in Ro60-immunized Balb/c. Balb/c mice were immunized with
Ro60 peptide or PBS (mock) in the tailbase or the abdominal area. Plasma from all animals were analyzed at the indicated time points for anti-MAP-
Ro60 antibodies (A). The same mice were analyzed for pilocarpine stimulated salivary flow (B). Data shown are mean values +/- SEM for 10 mice/
group. Significant differences are indicated (*** p,0.0001; * p,0.05) and were determined by unpaired Student’s t-test. D: number of days post
primary injection.
doi:10.1371/journal.pone.0018003.g001
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mice can lead to a decrease in salivary flow. Furthermore, our
comparison of immunization sites suggests that impaired SG
function is affected by the site of injection.
Salivary gland dysfunction is dependent on activation of
Th1 cells
In order to understand the mechanism associated with the change in
SFR following immunization in the abdominal area, as well as the
direct role of the Ro60 peptide activated lymphocytes, cytokine
expression was tested in cultures obtained from splenocytes re-
stimulated with Ro60 peptide (Table 1). In the spleen, Ro60 specific
cells from the abdominal area injected mice produced consistently
higher levels of cytokines, e.g. IFN-c,I L - 1 2 ,a n dI L - 1 0 ,c o m p a r e dw i t h
PBS or tailbase treated mice (Table 1). These data suggest a direct
stimulation of Ro60 peptide on the splenic T cells when administered in
vivo. In addition, the higher levels of cytokines in mice injected in the
abdominal area further supports the abdominal area as the optimal
delivery site for Ro60 antigen to the systemic immune system.
We also analyzed cytokines in SG homogenates from tailbase or
abdominal area immunized mice on day 95 post primary
immunization. Data obtained from SG homogenates showed Th1
cell activation with elevated IFN-c and IL-12, in abdominal area
immunized mice compared with either PBS control or tailbase
immunized mice (Table 2). This local effect on the SG further suggests
a role for Th1 cytokines in the loss of SG activity in this model.
Previousresearchwithotherimmunizationmodelsofautoimmune
disease has suggested that the use of other strains of mice, different
forms of peptide, or the use of secondary adjuvants can enhance
disease onset and penetrance. Therefore, we tested disease induction
in the autoimmune prone SJL/J mouse strain. This strain of mice has
been shown to have salivary gland dysfunction following over
expression of IL-12 in the thyroid gland [4]. In addition, we
immunized with a MAP version of the Ro60 peptide, which is known
to induce higher titers of antibodies [12,13], and added a secondary
adjuvant (PTX), which has been reported to be critical for disease
induction in some strains of mice for experimental autoimmune
uveoretinitis [11], and studied the effect on disease induction.
SJL/J mice do not develop autoantibodies after MAP-
Ro60 immunization
Previous research demonstrated that Ro60 peptide immunization
can trigger antibody formation against the whole 60-kDa Ro protein
[14]. In contrast to the experience in Balb/c mice, MAP-Ro60
immunization of female SJL/J mice only resulted in a significant
induction of antibodies compared with PBS immunized mice after
the third boost in tailbase immunized + PTX mice (p=0.03,
Figure 2A). Furthermore, no difference in antibodies levels was
observed in the mice immunized abdominally +/- PTX (Figure 2B).
It is not clear if the origin of anti-SSA/Ro and anti-SSB/La is
linked, but epitope spreading after immunization has been
reported [14]. Therefore we tested if immunization with Ro60
peptides could induce antibodies against the La antigen. In both
tailbase and abdominal area immunized SJL/J mice, no increase
in the mean titer of anti-SSB/La antibodies was detected
(Figure 2C). However, 1 out of 4 mice clearly developed anti-La
antibodies in MAP-Ro60 + PTX immunized mice at each
injection site. These data show that MAP-Ro60 immunization
does not lead to a more pronounced anti-MAP-Ro60 antibody
production in SJL/J mice. Despite the lack of significant antibody
formation in response to the immunization peptide, anti-La
antibodies were detected in some of the Ro60 immunized mice
indicating a low level of epitope spreading.
No changes in focus score in MAP-Ro60 immunized SJL/J
mice
SGs from immunized SJL/J mice were analyzed for lympho-
cytic infiltrates at the end of the study. In general, SJL/J mice
Table 2. Salivary gland cytokines in Ro60-immunized Balb/c mice.
Th1- Th17- Th2-
IFN-c IL-12p40 IL-18 IL-17 IL-4 IL-10
PBS 21.3 6.8 165.4 3.2 8.0 12.5
SG homogenates Ro60-Tail 27.0 6.7 88.5 4.0 7.2 16.1
Ro60-Abdominal area 50.8 13.5 172.1 6.6 10.3 14.3
Cytokine levels in the SG were determined after extraction of soluble protein from the SGs and correction for total protein concentration. Data from SG protein extracts
are the mean (pg/mL) of 3 random samples from 10 mice/group for one experiment.
doi:10.1371/journal.pone.0018003.t002
Table 1. Cytokine production after Ro60 peptide re-stimulated splenocytes from Balb/c mice.
Th1- Th17- Th2-
IFN-c IL-12p40 IL-18 IL-17 IL-4 IL-10
PBS 1.9 3.9 0.8 0.2 0.0 3.3
Splenocytes Ro60-Tail 156.6 82.2 29.4 51.4 3.2 33.5
Ro60-Abdominal area 313.9 146.7 32.8 36.6 2.7 42.2
Splenocytes were pooled from 10 mice/group. Culture supernatants were collected following incubation with or without (medium controls) Ro60 peptide and analyzed
for levels of the indicated cytokines (in pg/mL). Cytokine levels from the medium controls were subtracted from the Ro60 peptide treated cells and the mean of each
duplicate was used in this table.
doi:10.1371/journal.pone.0018003.t001
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score (average 0.39) at baseline. Although the addition of PTX to
MAP-Ro60 immunized mice compared to PBS controls tended to
increase the mean focus scores for the tailbase (0.88 versus 0.42,
p=0.15) and abdominal area (0.59 versus 0.36, p=0.20) injection
sites, this increase did not reach statistical significance (Figure 3).
These data show that SJL mice are not more prone to the
development of SG infiltrates after immunization. In addition,
immunization with a modified Ro60 peptide, MAP-Ro60, does
also not lead to an increased focus score. The use of an extra
adjuvant, PTX, did not increase SG inflammation.
Optimal decrease in salivary flow is dependent on the
injection site and use of an adjuvant
Mice immunized in the tailbase showed a transient drop in SG
function on day 17 that was only significant for the + PTX group
(p=0.04, Figure 4A). However, a sustained decrease in saliva
production was seen when the abdominal area was immunized
(p=0.04 and p=0.04 for day 70 and 95 respectively) and was
more pronounced with the addition of PTX (p=0.04 and
p,0.001 for day 70 and 95 respectively, Figure 4B). Although,
these data suggest that the presentation of the antigenic peptide
(conventional versus MAP) or the use of SJL mice does not affect
the time of onset of SG dysfunction following Ro60 peptide
immunization, it does confirm the site of injection as being
important in disease induction. Furthermore, the addition of PTX
can increase SG impairment.
MAP-Ro60 peptide increased IFN-c producing
lymphocytes
Our study with Balb/c mice suggested that proinflammatory
cytokines play a critical role in the loss of salivary gland activity in
these mice. To further study if activated T cells were involved
directly in the decreased SG function in the SJL mice, Th1 and
Th17 populations were identified in isolated cells (day 10 post
primary immunization) from associated lymph nodes (LNs) of the
SGs. Around 1% IFN-c+CD4+/- cells were found in control mice.
In contrast, immunization with MAP-Ro60 +/- PTX increased
IFN-c+ cells (,4-5% CD4+/- cells, Figure 5); no significant
change in Th17 (CD4+IL-17+) was observed (data not shown).
These data suggest that injection with MAP-Ro60 peptide
promotes IFN-c release from lymphocytes, localized in the SG
LNs. This further confirms that the increase in IFN-c might play a
direct role in SG impairment.
Discussion
The involvement of the Ro (SSA) antigen and anti-Ro
antibodies in SS is shown in several studies [15,16]. The majority
of SS patients are seropositive for anti-Ro antibodies and these
antibodies have been described to correlate with diseases activity
[17]. These data suggest an important role for anti-Ro antibodies
in SS, but the exact relevance of this antibody has not been
elucidated yet.
In animal models, it has been shown that repetitive immuni-
zation with a Ro60 peptide or Ro60 protein can induce a mild SS-
like disease, with reduced salivary flow and a low grade monocytic
infiltration of the SG. Several controls in these studies, such as
reverse and scrambled peptides as well as MAP backbone
immunization, have established the specificity of the immune
response to Ro
273–289 [18]. However, the mechanism by which
Ro60-immunization causes SS is still unknown. A direct
debilitating effect of the autoantibodies is unlikely, since only
several re-immunizations induce the onset of the disease and the
presence of antibodies does not directly correlate with salivary
gland dysfunction [5]. We therefore wanted to reproduce the
effects of Ro60-immunization in Balb/c mice as previously
described [5], and studied the cytokines that accompanied the
SG dysfunction in order to get more insight into this phenomenon.
Ro60 immunized Balb/c mice developed autoantibodies to
Ro60 peptide as expected. Over time, decreased salivary flow was
observed as previously described [5]. When mice were immunized
in the abdominal area as opposed to the tail base, more
pronounced loss of function was observed. Recently, other
investigators reported a similar injection site specific effects, in
which flank injection with an autoantigen in an experimental
autoimmune encephalomyelitis (EAE) mouse model was shown to
be more effective in eliciting disease compared to footpad and
tailbase injection [19].
Since the induction of antibodies was not significantly different
between tailbase or abdominal area immunized Balb/c mice, this
cannot be explained by a direct effect of these autoantibodies on
SG dysfunction. Furthermore, SJL/J mice immunized with Ro60
peptide did not show anti-MAP-Ro60 antibodies or increased
focus scores, again suggesting these changes do not directly
Figure 3. Unchanged salivary gland lymphocytic infiltrates in
SJL/J mice. SGs from all animals used for saliva collection, were
analyzed at the end of the study for lymphocytic infiltrates. The score of
each mouse is shown individually. The location of injection is indicated.
Data shown are mean values. P-values are indicated and were
determined by unpaired Student’s t-test.
doi:10.1371/journal.pone.0018003.g003
Figure 2. Induction of autoantibodies in SJL/J mice. Plasma from all animals used for saliva collection, were analyzed at the indicated time
points for anti-MAP-Ro60 antibodies (A-B) or at the end of the study for anti-La antibodies (N=4/group) (C). The location of injection is indicated.
Data shown are mean values +/- SD (A-B) or the mean value alone (C). The P-value is indicated (* p,0.05) and was determined by unpaired
Student’s t-test.
doi:10.1371/journal.pone.0018003.g002
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pro-inflammatory cytokines could be involved. Ro60-specific cells
in the spleen of the abdominal area immunized Balb/c mice that
developed xerostomia, produced consistently higher levels of IFN-
c and IL-12, compared with PBS or tailbase immunized mice.
Also SG extracts of these mice contained higher levels of both
IFN-c and IL-12. This suggests that immunization in the
abdominal area induces a more vigorous immune response than
immunization at the tailbase, but the exact pathway remains to be
elucidated. These data also emphasize the effect of IFN-c on the
salivary gland dysfunction in Ro60 peptide immunized Balb/c,
and add to data that show the important role of IFN-c on the
growth and function of human SG cells [7,8]. It also confirms the
importance of IL-12 in SG dysfunction, as we have previously
demonstrated in IL-12 transgenic mice [4].
It isfurthernotable that thelevel ofSG lymphocyticinfiltrates did
not correlate with changes in cytokines in the SG. Conceivably,
systemic cytokines induced by Ro60-immunization circulate from
the spleen and draining lymph nodes into the SG, or the epithelial
cells within the SG serve as ‘‘lymphoid’’ cells and produce cytokines
locally that later impair the function of the gland [20]. As shown for
Balb/c mice, increased IFN-c positive cells in the SG associated
LNs of SJL/J following Ro60 peptide immunization also suggests
the underlying mechanism of xerostomia is related to IFN-c
production. Overall, these data suggest that a Th1 cell mediated
immune response with the secretion of cytokines plays a crucial role
in the xerostomia observed in this model.
In conclusion, our data first show that reduced SG activity after
repeated immunization is affected by the injection site: with the
abdominal area injection leading to a more immunogenic and
Figure 4. Salivary gland dysfunction in SJL/J immunized with MAP-Ro60 +/- PTX. SJL/J mice were immunized with MAP-Ro60 +/- PTX or
PBS (mock) in the tailbase (A) or the abdominal area (B). Data shown are mean values +/- SEM for 10 mice/group. Significant differences are indicated
(*** p,0.0001; * p,0.05) and were determined by unpaired Student’s t-test. D: number of days post primary injection.
doi:10.1371/journal.pone.0018003.g004
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which Ro60-immunization affects the salivary gland, appears to
involve the induction of a Th1 cell response, emphasizing the
crucial role of IFN-c in SG dysfunction.
Materials and Methods
Animals
Female Balb/c and SJL/J mice (N=80 and N=90 respective-
ly), 6–8 weeks old, were obtained from Jackson Laboratory (Bar
Harbor, ME). Animals were housed in a pathogen-free facility. All
procedures involving animals were performed in compliance with
the National Institutes of Health (NIH) Guidelines on Use of
Animals in Research. Animal protocols (#09-512) were approved
by the National Institute of Dental and Craniofacial Research
(NIDCR) Animal Care and Use Committee (ACUC) and the NIH
Biosafety Committee.
Peptides and immunization
Mice were immunized with Ro60 peptide as described earlier
[21]. The following peptides (University of Oklahoma Health
Sciences Molecular BiologycoreFacility, Oklahoma City, OK) were
used in this study: Ro
273–289 (NH2-Leu-Gln-Glu-Met-Pro-Leu-Thr-Ala-
Leu-Leu-Arg-Asn-Leu-Gly-Lys-Met-Thr-COOH) for Balb/c immuniza-
tion and MAP-Ro
273–289 ((NH2-Leu-Gln-Glu-Met-Pro-Leu-Thr-Ala-
Leu-Leu-Arg-Asn-Leu-Gly-Lys-Met-Thr-Cys)8-COOH) for SJL/J immu-
nization and for detection of anti-Ro60 antibodies in ELISA (see
below). A MAP is made up of a hepta lysine backbone upon which
are built eight copies of the same peptide sequence (in this case 8
copies of Ro
273–289). A MAP behaves like a low molecular weight
protein. Briefly, on day 0 mice were immunized with 100 mgR o 6 0
peptide or phosphate buffered saline (PBS; Invitrogen, Carlsbad,
CA) emulsified (1:1) in complete Freund’s adjuvant (CFA, Sigma-
Aldrich, St. Louis, MO). Subsequently, animals were immunized
with an equal amount of Ro60 peptide or PBS (1:1) in incomplete
Freund’s adjuvant (IFA, Sigma-Aldrich, St. Louis, MO) on days 17,
37 and 70 post primary immunization (100 ml per animal) and
sacrificed at day 95. Two subcutaneous (s.c.) injection sites were
tested:thetailbaseand the abdominalarea.A separate groupineach
experiment of SJL/J mice was injected intraperitoneal (i.p.) with
0.1 mg/mouse PTX in addition to each peptide boost.
Plasma preparation
For plasma preparation, blood was obtained via the retro-
orbital plexus with a hematocrit tube (Drummond Scientific
Company, Broomall, PA, USA) before each immunization.
Plasma was separated by centrifugation at 2300xg for 5 min and
stored at 280uC until further analysis.
Determination of autoantibodies
Plasma samples were analyzed for autoantibodies against SSA/
Ro and SSB/La. The enzyme-linked immunosorbant assay
(ELISA) used to detect 60-kD MAP-Ro
273–289 antibodies was
described earlier [21]. The autoantibody against SSB/La (total Ig)
was measured with a commercial available ELISA kit (Cat#5810,
Alpha Diagnostic International, San Antonio, TX) according to
the manufacturer’s protocol.
Saliva collection
Saliva was collected one day before each boost or sacrifice. Mice
differ in their sensitivity to pilocarpine, and the dose needs to be
optimized so that mice produce measurable amounts of saliva but
do not over salivate and die due to plugging of the airways
(personal observation). Optimal dosage of pilocarpine for Balb/c
in our laboratory was set at 0.2 mg/kg bodyweight (BW) and
0.35 mg/kg BW for SJL/J mice. Saliva secretion was induced by
s.c. injection of pilocarpine (Sigma-Aldrich, St. Louis, MO) and
whole saliva was collected for 20 min from the oral cavity, and the
volume was determined by weight.
Histopathology
Submandibular glands (SMG) were removed for standard
histological analysis using hematoxylin and eosin (H&E) staining
from mice at the time of sacrifice. Scoring of histological sections
was based on the focus score used in patients with SS [22]. Briefly,
one of two whole submandibular glands were removed for
histological analysis from at the time of sacrifice and placed O/
N in 10% formaline. After fixation, the tissues were dehydrated in
Figure 5. Increased IFN-c releasing lymphocytes in salivary gland associated lymph nodes from SJL/J mice. The SG lymph nodes cells
isolated from mice immunized with PBS (mock) or MAP-Ro60 +/- PTX were analyzed by flow cytometry assay for IFN-c+ and specifically CD4+ IFN-c+
(Th1) lymphocyte induction 10 days post primary immunization. The SG lymph node cells from one group (N=10) are pooled and divided into 2
samples. Data shown is from one representative experiment.
doi:10.1371/journal.pone.0018003.g005
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techniques. 3 sections from the middle of the gland were cut at
5 mm and subsequently stained with hematoxylin and eosin
(H&E). A focus is an aggregate of 50 or more lymphocytes and
histiocytes per 4 mm
2. Foci were counted through the whole
section, in a total of three sections per salivary gland using a 40x
magnification. The results were calculated and expressed as foci
per 4 mm
2. The focus scores were assessed blindly by two different
examiners and the mean scores were determined.
Detection of cytokines from cell cultures and SG
homogenates
Splenocytes obtained from treated mice were isolated and
cultured in 24-well plates at 5610
6 cells/mL RPMI-1640 medium
(Invitrogen, Carlsbad, CA), containing HL-1 serum replacement
(Cambrex Bioscience, Walkersville, MD), with or without 30 mg/
mL Ro60 peptide. Supernatants were collected after 48 hr
incubation.
Cytokine levels in the SG were determined after extraction of
soluble protein from the SGs and correction for total protein
concentration, which was determined with BCA
TM protein assay
kit (Pierce, Rockford, IL, USA). Cytokines were measured using a
multiplex sandwich-ELISA assay (Aushon Biosystem, Billerica,
MA). Duplicates for each sample were tested in three dilutions and
the mean values of the duplicates from the optimal dilution were
reported. Lower detection limits for this assay are: IL-4: 0.8 pg/
ml, IL-10: 1.6 pg/ml, IL-17: 1.6 pg/ml, IFN-c: 7.8 pg/ml.
Flow cytometric identification of CD4+ IFN-c+
lymphocytes
One million (10
6) associated lymph node cells from the SGs (SG
LN cells) were isolated and cultured in anti-CD3/anti-CD28
coated 24-well plate. Phorbol 12-myristate 13-acetate (PMA) and
ionomycin (Sigma-Aldrich, St. Louis, MO) were added during the
last 5 hr of total 48 hr incubation. Cells were harvested and
stained with PerCP conjugated anti-mouse CD4 (BD Pharmingen,
San Diego, CA) for 30 min on ice. Cells were fixed and
permeabilized by a Fixation/Permeabilization kit (BD Pharmin-
gen, San Diego, CA) and stained with allophycocyanin (APC)-
conjugated anti-mouse IFN-c (BD Pharmingen, San Diego, CA)
according manufacturer’s protocol. Data were acquired using a
FACSCalibur (BD Biosciences, San Diego, CA), and analyzed
using Flowjo software (Tree Star Inc., Ashland, OR).
Statistical analysis
One-way ANOVA and unpaired Student’s t-test were used to
compare differences between groups. All analyses were performed
with GraphPad Prism statistical software (GraphPad Software Inc.
version 5.01, La Jolla, CA) using a p value #0.05 as statistically
significant.
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